This case series describes 2 patients who underwent a single anesthesia strategy for definitive management of bilateral ground-glass opacities harboring adenocarcinoma-spectrum lesions using robotic navigational localization paired with robotic thoracoscopic resection.
KneuertzPJAbdel-RasoulMD’SouzaDM, et al. Segmentectomy for clinical stage I non-small cell lung cancer: national benchmarks for nodal staging and outcomes by operative approach. Cancer2022; 128: 1483–1492.
2.
ReisenauerJSimoffMJPritchettMA, et al. Ion: technology and techniques for shape-sensing robotic-assisted bronchoscopy. Ann Thorac Surg2022; 113: 308–315.
3.
OhdeYNagaiKYoshidaJ, et al. The proportion of consolidation to ground-glass opacity on high resolution CT is a good predictor for distinguishing the population of non-invasive peripheral adenocarcinoma. Lung Cancer2003; 42: 303–310.
4.
SuzukiKAsamuraHKusumotoM, et al. “Early” peripheral lung cancer: prognostic significance of ground glass opacity on thin-section computed tomographic scan. Ann Thorac Surg2002; 74: 1635–1639.
5.
LuCHHsiaoCHChangYC, et al. Percutaneous computed tomography-guided coaxial core biopsy for small pulmonary lesions with ground-glass attenuation. J Thorac Oncol2012; 7: 143–150.
6.
GaoRWBerryMFKunderCA, et al. Survival and risk factors for progression after resection of the dominant tumor in multifocal, lepidic-type pulmonary adenocarcinoma. J Thorac Cardiovasc Surg2017; 154: 2092–2099.
7.
AminMBEdgeSGreeneF, et al. (eds.). AJCC cancer staging manual. 8th ed.New York: Springer International Publishing, 2017.
8.
ZhouJLiYZhangY, et al. Solitary ground-glass opacity nodules of stage IA pulmonary adenocarcinoma: combination of 18F-FDG PET/CT and high-resolution computed tomography features to predict invasive adenocarcinoma. Oncotarget2017; 8: 23312–23321
9.
AltorkiNWangXKozonoD, et al. Lobar or sublobar resection for peripheral Stage IA non-small-cell lung cancer. N Engl J Med2023; 388: 489–498.
10.
SajiHOkadaMTsuboiM, et al. Segmentectomy versus lobectomy in small-sized peripheral non-small-cell lung cancer (JCOG0802/WJOG4607L): a multicentre, open-label, phase 3, randomised, controlled, non-inferiority trial. Lancet2022; 399: 1607–1617.
